Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis

Atherosclerotic coronary heart disease is the leading cause of morbidity and mortality in industrialized countries, and endothelial dysfunction is considered a precursor phenomenon. The nitric oxide produced by the endothelium under the action of endothelial nitric oxide synthase has important antiatherogenic functions. Its reduced bioavailabilty is the beginning of the atherosclerotic process. The addition of two methyl radicals to arginine, through the action of methyltransferase nuclear proteins, produces asymmetric dimethylarginine, which competes with L-arginine and promotes a reduction in nitric oxide formation in the vascular wall. The asymmetric dimethylarginine, which is itself considered a mediator of the vascular effects of the several risk factors for atherosclerosis, can be eliminated by renal excretion or by the enzymatic action of the dimethylarginine dimethylaminohydrolases. Several basic science and clinical research studies suggest that the increase in asymmetric dimethylarginine occurs in the context of chronic renal insufficiency, dyslipidemia, high blood pressure, diabetes mellitus, and hyperhomocysteinemy, as well as with other conditions. Therapeutic measures to combat atherosclerosis may reverse these asymmetric dimethylarginine effects or at least reduce the concentration of this chemical in the blood. Such an effect can be achieved with competitor molecules or by increasing the expression or activity of its degradation enzyme. Studies are in development to establish the true role of asymmetric dimethylarginine as a marker and mediator of atherosclerosis, with possible therapeutic applications. The main aspects of the formation and degradation of asymmetric dimethylarginine and its implication in the atherogenic process will be addressed in this article.

Saved in:
Bibliographic Details
Main Authors: Landim,Maurício Batista Paes, Casella Filho,Antônio, Chagas,Antônio Carlos Palandri
Format: Digital revista
Language:English
Published: Faculdade de Medicina / USP 2009
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322009000500015
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1807-59322009000500015
record_format ojs
spelling oai:scielo:S1807-593220090005000152009-06-18Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesisLandim,Maurício Batista PaesCasella Filho,AntônioChagas,Antônio Carlos Palandri Coronary heart disease Atherogenesis Endothelium Nitric oxide Asymmetric dimethylarginine Cardiovascular risk Atherosclerotic coronary heart disease is the leading cause of morbidity and mortality in industrialized countries, and endothelial dysfunction is considered a precursor phenomenon. The nitric oxide produced by the endothelium under the action of endothelial nitric oxide synthase has important antiatherogenic functions. Its reduced bioavailabilty is the beginning of the atherosclerotic process. The addition of two methyl radicals to arginine, through the action of methyltransferase nuclear proteins, produces asymmetric dimethylarginine, which competes with L-arginine and promotes a reduction in nitric oxide formation in the vascular wall. The asymmetric dimethylarginine, which is itself considered a mediator of the vascular effects of the several risk factors for atherosclerosis, can be eliminated by renal excretion or by the enzymatic action of the dimethylarginine dimethylaminohydrolases. Several basic science and clinical research studies suggest that the increase in asymmetric dimethylarginine occurs in the context of chronic renal insufficiency, dyslipidemia, high blood pressure, diabetes mellitus, and hyperhomocysteinemy, as well as with other conditions. Therapeutic measures to combat atherosclerosis may reverse these asymmetric dimethylarginine effects or at least reduce the concentration of this chemical in the blood. Such an effect can be achieved with competitor molecules or by increasing the expression or activity of its degradation enzyme. Studies are in development to establish the true role of asymmetric dimethylarginine as a marker and mediator of atherosclerosis, with possible therapeutic applications. The main aspects of the formation and degradation of asymmetric dimethylarginine and its implication in the atherogenic process will be addressed in this article.info:eu-repo/semantics/openAccessFaculdade de Medicina / USPClinics v.64 n.5 20092009-05-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322009000500015en10.1590/S1807-59322009000500015
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Landim,Maurício Batista Paes
Casella Filho,Antônio
Chagas,Antônio Carlos Palandri
spellingShingle Landim,Maurício Batista Paes
Casella Filho,Antônio
Chagas,Antônio Carlos Palandri
Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis
author_facet Landim,Maurício Batista Paes
Casella Filho,Antônio
Chagas,Antônio Carlos Palandri
author_sort Landim,Maurício Batista Paes
title Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis
title_short Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis
title_full Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis
title_fullStr Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis
title_full_unstemmed Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis
title_sort asymmetric dimethylarginine (adma) and endothelial dysfunction: implications for atherogenesis
description Atherosclerotic coronary heart disease is the leading cause of morbidity and mortality in industrialized countries, and endothelial dysfunction is considered a precursor phenomenon. The nitric oxide produced by the endothelium under the action of endothelial nitric oxide synthase has important antiatherogenic functions. Its reduced bioavailabilty is the beginning of the atherosclerotic process. The addition of two methyl radicals to arginine, through the action of methyltransferase nuclear proteins, produces asymmetric dimethylarginine, which competes with L-arginine and promotes a reduction in nitric oxide formation in the vascular wall. The asymmetric dimethylarginine, which is itself considered a mediator of the vascular effects of the several risk factors for atherosclerosis, can be eliminated by renal excretion or by the enzymatic action of the dimethylarginine dimethylaminohydrolases. Several basic science and clinical research studies suggest that the increase in asymmetric dimethylarginine occurs in the context of chronic renal insufficiency, dyslipidemia, high blood pressure, diabetes mellitus, and hyperhomocysteinemy, as well as with other conditions. Therapeutic measures to combat atherosclerosis may reverse these asymmetric dimethylarginine effects or at least reduce the concentration of this chemical in the blood. Such an effect can be achieved with competitor molecules or by increasing the expression or activity of its degradation enzyme. Studies are in development to establish the true role of asymmetric dimethylarginine as a marker and mediator of atherosclerosis, with possible therapeutic applications. The main aspects of the formation and degradation of asymmetric dimethylarginine and its implication in the atherogenic process will be addressed in this article.
publisher Faculdade de Medicina / USP
publishDate 2009
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322009000500015
work_keys_str_mv AT landimmauriciobatistapaes asymmetricdimethylarginineadmaandendothelialdysfunctionimplicationsforatherogenesis
AT casellafilhoantonio asymmetricdimethylarginineadmaandendothelialdysfunctionimplicationsforatherogenesis
AT chagasantoniocarlospalandri asymmetricdimethylarginineadmaandendothelialdysfunctionimplicationsforatherogenesis
_version_ 1756432043650056192